More forecasts: Atlanta 30 day forecast
Gilead Sciences Buys CymaBay Therapeutics for $4.3B, Boosting Liver Disease Treatment Options
Feb 13, 2024
Gilead Sciences is acquiring CymaBay Therapeutics for $4.3 billion, enhancing its liver disease portfolio with seladelpar, a drug for primary biliary cholangitis.
UMass Amherst Study Reveals Higher Gas Costs for Drivers in Massachusetts' Lower-Income Areas Due to Poor Roads
Feb 12, 2024
A UMass Amherst study found that poor road conditions in Massachusetts' disadvantaged areas cause higher fuel consumption, disproportionately affecting these communities financially.












